Abstract:Neurotropic viruses may cause meningitis, myelitis, encephalitis, or meningoencephalitis. These inflammatory conditions of the central nervous system (CNS) may have serious and devastating consequences if not treated adequately. In this review, we first summarize how neurotropic viruses can enter the CNS by (1) crossing the blood-brain barrier or blood-cerebrospinal fluid barrier; (2) invading the nose via the olfactory route; or (3) invading the peripheral nervous system. Neurotropic viruses may then enter the intracellular space of brain cells via endocytosis and/or membrane fusion. Antiviral drugs are currently used for different viral CNS infections, even though their use and dosing regimens within the CNS, with the exception of acyclovir, are minimally supported by clinical evidence. We therefore provide considerations to optimize drug treatment(s) for these neurotropic viruses. Antiviral drugs should cross the blood-brain barrier/blood cerebrospinal fluid barrier and pass the brain cellular membrane to inhibit these viruses inside the brain cells. Some antiviral drugs may also require intracellular conversion into their active metabolite(s). This illustrates the need to better understand these mechanisms because these processes dictate drug exposure within the CNS that ultimately determine the success of antiviral drugs for CNS infections. Finally, we discuss mathematical model-based approaches for optimizing antiviral treatments. Thereby emphasizing the potential of CNS physiologically based pharmacokinetic models because direct measurement of brain intracellular exposure in living humans faces ethical restrictions. Existing physiologically based pharmacokinetic models combined with in vitro pharmacokinetic/pharmacodynamic information can be used to predict drug exposure and evaluate efficacy of antiviral drugs within the CNS, to ultimately optimize the treatments of CNS viral infections.

Modulating Immune Response in Viral Infection for Quantitative Forecasts of Drug Efficacy

The efficacy of antiviral drug, HIV viral load and the immune response

Viral Kinetics Model of SARS‐CoV‐2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection

Compositional modelling of immune response and virus transmission dynamics

Dynamics of Activation and Regulation of the Immune Response to Attack by Viral Pathogens Using Mathematical Modeling

Comparing antiviral strategies against COVID-19 via multiscale within-host modelling

CNS Viral Infections-What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches

Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics

Dynamical Modelling of Viral Infection and Cooperative Immune Protection in COVID-19 Patients.

Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer

Exploring Immune Responses through Dynamic Modeling of Cell‐Immune Interactions in Viral Infection and Vaccination

Modeling Antiretroviral Drug Responses for HIV-1 Infected Patients Using Differential Equation Models.

Recent approaches in computational modelling for controlling pathogen threats

Optimal control strategies to tailor antivirals for acute infectious diseases in the host

Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics

Modelling of immune cells as vectors of HIV spread inside a patient human body

Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treatments

In Vivo HIV Dynamics, Modeling the Interaction of HIV and Immune System Via Non-Integer Derivatives

Modeling Influenza Virus Infection: A Roadmap for Influenza Research

System-Based Approaches to Delineate the Antiviral Innate Immune Landscape

Quantitative Prediction of Human Immunodeficiency Virus Drug Resistance